Marine organisms from invertebrates to extremophiles produce antimicrobial peptides with unique properties that could help combat the global antibiotic resistance crisis, with new discovery tools accelerating their development.
Low resistance propensity + broad-spectrum activityMarine-derived AMPs kill pathogens through membrane disruption mechanisms that are difficult for bacteria to evolve resistance against, unlike conventional antibiotics
What the researchers found
Marine-derived antimicrobial peptides (AMPs), sourced from invertebrates, extremophiles, and cyanobacteria, exhibit broad-spectrum activity against drug-resistant pathogens through membrane disruption and immunomodulation. These cationic, amphipathic molecules show low resistance propensity and multifunctional bioactivity spanning antimicrobial, antioxidant, and anticancer properties. Advances in machine learning, genomic/metagenomic tools, and synthetic biology are revolutionizing AMP discovery and optimization. Biotechnological innovations in heterologous expression and marine biomass valorization support scalable production aligned with circular economy principles.
Why it matters
Antimicrobial resistance (AMR) is projected to cause 10 million deaths annually by 2050. Marine organisms are an underexplored reservoir of antimicrobial peptides that have evolved over billions of years to combat pathogens in one of Earth's most microbially diverse environments. Their unique structural features — shaped by extreme ocean conditions — give them properties that land-derived peptides often lack, making them promising candidates for next-generation anti-infective drugs.
The numbers in context
Sources: invertebrates, extremophiles, cyanobacteria · Broad-spectrum activity · Low resistance propensity · Multifunctional: antimicrobial + antioxidant + anticancer · Applications: healthcare, aquaculture, food safety, environmental remediation
How the study worked
Comprehensive review covering the discovery, structural features, mechanisms of action, biotechnological production, and applications of marine-derived AMPs. Discusses genomic/metagenomic mining, machine learning-based peptide prediction, synthetic biology approaches, and circular bioeconomy frameworks for sustainable commercialization.
Who was studied
Review of marine-derived antimicrobial peptides from diverse ocean organisms and their biotechnological applications
What this study cannot tell us
As a review, no new experimental data is presented. The abstract acknowledges critical challenges including production scalability, regulatory frameworks, and the gap between laboratory discovery and commercial application. Many marine AMPs described in the literature have not progressed beyond in vitro characterization.
How to read the evidence
This is a comprehensive review article providing a broad overview of the field. While it synthesizes substantial research, most marine AMPs discussed remain in early-stage discovery or preclinical development, with limited clinical trial data available.
When this study was published
Published in 2026, this is a very current review reflecting the latest advances in marine peptide discovery, including AI/ML-driven approaches and synthetic biology tools that have only recently become available.
The bigger picture
The ocean covers 70% of Earth's surface and harbors enormous biodiversity that remains largely unexplored for therapeutic potential. Marine-derived AMPs represent a convergence of several trends: the urgent need for new antimicrobials, advances in computational biology and AI for drug discovery, and growing interest in sustainable blue economy approaches. As the antimicrobial resistance crisis worsens, the ocean's peptide arsenal could become an increasingly critical resource for global health.
Questions still open
- Which marine AMPs are closest to clinical development, and what are the main regulatory hurdles for approval?
- Can machine learning-guided optimization produce marine AMP variants with improved human biocompatibility and pharmacokinetics?
- How can marine AMP production be scaled sustainably without depleting ocean biodiversity?
Common questions
Why are ocean organisms good sources of antimicrobial peptides?
How is artificial intelligence helping discover new marine antimicrobial peptides?
Read the original research
Marine-derived antimicrobial peptides (AMPs): Blue biotechnological assets for sustainable healthcare and circular bioeconomy.
Advances in protein chemistry and structural biology, 149, 171-201
Citation
Selvaraj, Chandrabose; Desai, Deepali; Santos-Villalobos, Sergio de Los; Jayaprakashvel, Mani; Muthezhilan, Radhakrishnan; Singh, Sanjeev Kumar. (2026). Marine-derived antimicrobial peptides (AMPs): Blue biotechnological assets for sustainable healthcare and circular bioeconomy.. Advances in protein chemistry and structural biology, 149, 171-201. https://doi.org/10.1016/bs.apcsb.2025.08.002